Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Identification of a novel diagnostic gene expression signature to discriminate uterine leiomyoma from leiomyosarcoma.

Adams CL, Dimitrova I, Post MD, Gibson L, Spillman MA, Behbakht K, Bradford AP.

Exp Mol Pathol. 2019 Oct;110:104284. doi: 10.1016/j.yexmp.2019.104284. Epub 2019 Jul 10.

PMID:
31301306
2.

CBX2 identified as driver of anoikis escape and dissemination in high grade serous ovarian cancer.

Wheeler LJ, Watson ZL, Qamar L, Yamamoto TM, Post MD, Berning AA, Spillman MA, Behbakht K, Bitler BG.

Oncogenesis. 2018 Nov 26;7(11):92. doi: 10.1038/s41389-018-0103-1.

3.

A Woman in Full.

Spillman MA, Sade RM.

Am J Bioeth. 2018 Jul;18(7):32-34. doi: 10.1080/15265161.2018.1478028. No abstract available.

PMID:
30040572
4.

A tRNA fragment, tRF5-Glu, regulates BCAR3 expression and proliferation in ovarian cancer cells.

Zhou K, Diebel KW, Holy J, Skildum A, Odean E, Hicks DA, Schotl B, Abrahante JE, Spillman MA, Bemis LT.

Oncotarget. 2017 Sep 8;8(56):95377-95391. doi: 10.18632/oncotarget.20709. eCollection 2017 Nov 10.

5.

A method for extracting and characterizing RNA from urine: For downstream PCR and RNAseq analysis.

Zhou K, Spillman MA, Behbakht K, Komatsu JM, Abrahante JE, Hicks D, Schotl B, Odean E, Jones KL, Graner MW, Bemis LT.

Anal Biochem. 2017 Nov 1;536:8-15. doi: 10.1016/j.ab.2017.08.003. Epub 2017 Aug 10.

6.

Fascin Is Associated With Aggressive Behavior and Poor Outcome in Uterine Carcinosarcoma.

Richmond AM, Blake EA, Torkko K, Smith EE, Spillman MA, Post MD.

Int J Gynecol Cancer. 2017 Nov;27(9):1895-1903. doi: 10.1097/IGC.0000000000001077.

PMID:
28704324
7.

PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines.

Nakachi I, Helfrich BA, Spillman MA, Mickler EA, Olson CJ, Rice JL, Coldren CD, Heasley LE, Geraci MW, Stearman RS.

Clin Transl Sci. 2016 Dec;9(6):293-301. doi: 10.1111/cts.12413. Epub 2016 Oct 20.

8.

Claudin-4 activity in ovarian tumor cell apoptosis resistance and migration.

Hicks DA, Galimanis CE, Webb PG, Spillman MA, Behbakht K, Neville MC, Baumgartner HK.

BMC Cancer. 2016 Oct 11;16(1):788.

9.

Reply.

Shalowitz DI, Spillman MA, Morgan MA.

Am J Obstet Gynecol. 2016 Dec;215(6):811. doi: 10.1016/j.ajog.2016.07.054. Epub 2016 Aug 2. No abstract available.

PMID:
27496688
10.

Interactions with industry under the Sunshine Act: an example from gynecologic oncology.

Shalowitz DI, Spillman MA, Morgan MA.

Am J Obstet Gynecol. 2016 Jun;214(6):703-7. doi: 10.1016/j.ajog.2016.02.035. Epub 2016 Feb 20.

PMID:
26902988
11.

Progestin treatment decreases CD133+ cancer stem cell populations in endometrial cancer.

Guy MS, Qamar L, Behbakht K, Post MD, Sheeder J, Sartorius CA, Spillman MA.

Gynecol Oncol. 2016 Mar;140(3):518-26. doi: 10.1016/j.ygyno.2015.12.022. Epub 2015 Dec 28.

PMID:
26731726
12.

High LIN28A Expressing Ovarian Cancer Cells Secrete Exosomes That Induce Invasion and Migration in HEK293 Cells.

Enriquez VA, Cleys ER, Da Silveira JC, Spillman MA, Winger QA, Bouma GJ.

Biomed Res Int. 2015;2015:701390. doi: 10.1155/2015/701390. Epub 2015 Oct 25.

13.

Cytokeratin 5-Positive Cells Represent a Therapy Resistant subpopulation in Epithelial Ovarian Cancer.

Corr BR, Finlay-Schultz J, Rosen RB, Qamar L, Post MD, Behbakht K, Spillman MA, Sartorius CA.

Int J Gynecol Cancer. 2015 Nov;25(9):1565-73. doi: 10.1097/IGC.0000000000000553.

14.

Lymphovascular space invasion in robotic surgery for endometrial cancer.

Hopkins MR, Richmond AM, Cheng G, Davidson S, Spillman MA, Sheeder J, Post MD, Guntupalli SR.

JSLS. 2014 Jul-Sep;18(3). pii: e2014.00021. doi: 10.4293/JSLS.2014.00021.

15.

I, robotic surgeon.

Spillman MA, Sade RM.

Virtual Mentor. 2014 Oct 1;16(10):813-7. doi: 10.1001/virtualmentor.2014.16.10.stas2-1410. No abstract available.

16.

A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.

Powell MA, Sill MW, Goodfellow PJ, Benbrook DM, Lankes HA, Leslie KK, Jeske Y, Mannel RS, Spillman MA, Lee PS, Hoffman JS, McMeekin DS, Pollock PM.

Gynecol Oncol. 2014 Oct;135(1):38-43. doi: 10.1016/j.ygyno.2014.07.083. Epub 2014 Jul 11.

17.

Gynecologic biopsy for molecular profiling: a review for the interventional radiologist.

Corr BR, Behbakht K, Spillman MA.

Semin Intervent Radiol. 2013 Dec;30(4):417-24. doi: 10.1055/s-0033-1359738. Review.

18.

Outcomes of women with atypical glandular cells on preoperative cytology and endometrial cancer.

Guy MS, Cheng G, Post MD, Spillman MA, Behbakht K, Davidson S, Sheeder J, Guntupalli SR.

Int J Gynecol Cancer. 2014 Feb;24(2):266-71. doi: 10.1097/IGC.0000000000000027.

PMID:
24401985
19.

Correction: Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research.

Anglesio MS, Wiegand KC, Melnyk N, Chow C, Salamanca C, Prentice LM, Senz J, Yang W, Spillman MA, Cochrane DR, Shumansky K, Shah SP, Kalloger SE, Huntsman DG.

PLoS One. 2013 Sep 27;8(9). doi: 10.1371/annotation/ffcaf179-872f-470b-8bb6-f06d8ba6d03a. eCollection 2013.

20.

Type-specific cell line models for type-specific ovarian cancer research.

Anglesio MS, Wiegand KC, Melnyk N, Chow C, Salamanca C, Prentice LM, Senz J, Yang W, Spillman MA, Cochrane DR, Shumansky K, Shah SP, Kalloger SE, Huntsman DG.

PLoS One. 2013 Sep 4;8(9):e72162. doi: 10.1371/journal.pone.0072162. eCollection 2013. Erratum in: PLoS One. 2013;8(10). doi:10.1371/annotation/856f0890-9d85-4719-8e54-c27530ac94f4. PLoS One. 2013;8(9). doi:10.1371/annotation/ffcaf179-872f-470b-8bb6-f06d8ba6d03a.

21.

Copy neutral loss of heterozygosity is more frequent in older ovarian cancer patients.

Pedersen BS, Konstantinopoulos PA, Spillman MA, De S.

Genes Chromosomes Cancer. 2013 Sep;52(9):794-801. doi: 10.1002/gcc.22075. Epub 2013 May 28.

22.

We need a new paradigm in gynecologic cancer care: SGO proposes solutions for delivery, quality and reimbursement policies.

Alvarez RD, Gray HJ, Timmins PF 3rd, Gibb RK, Edelson M, Fowler JM, Havrilesky LJ, McCauley DL, Nash JD, Rahaman J, Rash JK, Rodabaugh KJ, Powell MA, Bristow RE, Brown JV, Tewari D, Cliby WA, Anastasia P, Robinson WR 3rd, Shahin MS, Cantrell LA, Cloven NG, Gold MA, Hope JM, Muntz HG, Sorosky JI, Elkas JC, Frumovitz MM, Jewell E, Spillman MA, Naumann RW.

Gynecol Oncol. 2013 Apr;129(1):3-4. No abstract available.

PMID:
23638463
23.

Claudins play a role in normal and tumor cell motility.

Webb PG, Spillman MA, Baumgartner HK.

BMC Cell Biol. 2013 Mar 23;14:19. doi: 10.1186/1471-2121-14-19.

24.

Risk-reducing salpingectomy as preventative strategy for pelvic serous cancer.

Anderson CK, Wallace S, Guiahi M, Sheeder J, Behbakht K, Spillman MA.

Int J Gynecol Cancer. 2013 Mar;23(3):417-21. doi: 10.1097/IGC.0b013e3182849dba. Review.

PMID:
23385282
25.

Estrogen switches pure mucinous breast cancer to invasive lobular carcinoma with mucinous features.

Jambal P, Badtke MM, Harrell JC, Borges VF, Post MD, Sollender GE, Spillman MA, Horwitz KB, Jacobsen BM.

Breast Cancer Res Treat. 2013 Jan;137(2):431-48. doi: 10.1007/s10549-012-2377-x. Epub 2012 Dec 18.

26.

Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel.

Cittelly DM, Dimitrova I, Howe EN, Cochrane DR, Jean A, Spoelstra NS, Post MD, Lu X, Broaddus RR, Spillman MA, Richer JK.

Mol Cancer Ther. 2012 Dec;11(12):2556-65. doi: 10.1158/1535-7163.MCT-12-0463. Epub 2012 Oct 16.

27.

DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.

Korch C, Spillman MA, Jackson TA, Jacobsen BM, Murphy SK, Lessey BA, Jordan VC, Bradford AP.

Gynecol Oncol. 2012 Oct;127(1):241-8. doi: 10.1016/j.ygyno.2012.06.017. Epub 2012 Jun 16.

28.

Specificity and prognostic validation of a polyclonal antibody to detect Six1 homeoprotein in ovarian cancer.

Qamar L, Deitsch E, Patrick AN, Post MD, Spillman MA, Iwanaga R, Thorburn A, Ford HL, Behbakht K.

Gynecol Oncol. 2012 May;125(2):451-7. doi: 10.1016/j.ygyno.2012.02.007. Epub 2012 Feb 12.

29.

Obstetricians: women's advocates, not adversaries.

Ralston SJ, Spillman MA, Mitchell MF, Mahoney J, Joseph GF Jr.

Am J Bioeth. 2011 Dec;11(12):57-9. doi: 10.1080/15265161.2011.613525. No abstract available.

PMID:
22146036
30.

Until debt do us part.

Spillman MA, Sgo Government Relations Committee.

Gynecol Oncol. 2011 Dec;123(3):455. doi: 10.1016/j.ygyno.2011.10.018. Epub 2011 Oct 20. No abstract available.

PMID:
22020038
31.

Surgical risk score predicts suboptimal debulking or a major perioperative complication in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Stashwick C, Post MD, Arruda JS, Spillman MA, Behbakht K, Davidson SA, Kelly MG.

Int J Gynecol Cancer. 2011 Nov;21(8):1422-7. doi: 10.1097/IGC.0b013e31822c7704.

PMID:
21997170
32.

Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells.

Wang Y, Sheng Q, Spillman MA, Behbakht K, Gu H.

Oncogene. 2012 May 17;31(20):2512-20. doi: 10.1038/onc.2011.435. Epub 2011 Sep 26.

33.

Does fortune foul fidelity?

Spillman MA, Sade R.

Am J Bioeth. 2011 Sep;11(9):14-5. doi: 10.1080/15265161.2011.593688. No abstract available.

PMID:
21877965
34.

Unliganded progesterone receptors attenuate taxane-induced breast cancer cell death by modulating the spindle assembly checkpoint.

Badtke MM, Jambal P, Dye WW, Spillman MA, Post MD, Horwitz KB, Jacobsen BM.

Breast Cancer Res Treat. 2012 Jan;131(1):75-87. doi: 10.1007/s10549-011-1399-0. Epub 2011 Feb 22.

35.

Large cell neuroendocrine carcinoma of the cervix: prognostic factors and survival advantage with platinum chemotherapy.

Embry JR, Kelly MG, Post MD, Spillman MA.

Gynecol Oncol. 2011 Mar;120(3):444-8. doi: 10.1016/j.ygyno.2010.11.007. Epub 2010 Dec 7.

PMID:
21138780
36.

Tissue-specific pathways for estrogen regulation of ovarian cancer growth and metastasis.

Spillman MA, Manning NG, Dye WW, Sartorius CA, Post MD, Harrell JC, Jacobsen BM, Horwitz KB.

Cancer Res. 2010 Nov 1;70(21):8927-36. doi: 10.1158/0008-5472.CAN-10-1238. Epub 2010 Oct 19.

37.

SGO Washington Update: the price of a profession.

Spillman MA.

Gynecol Oncol. 2010 Oct;119(1):3-4. doi: 10.1016/j.ygyno.2010.07.029. Epub 2010 Aug 13. No abstract available.

PMID:
20708785
38.

Progesterone receptor action: translating studies in breast cancer models to clinical insights.

Lange CA, Sartorius CA, Abdel-Hafiz H, Spillman MA, Horwitz KB, Jacobsen BM.

Adv Exp Med Biol. 2008;630:94-111. Review.

PMID:
18637487
39.

Clinical trials of xenotransplantation: waiver of the right to withdraw from a clinical trial should be required.

Spillman MA, Sade RM.

J Law Med Ethics. 2007 Summer;35(2):265-72. Review.

PMID:
17518852
40.

Regulation of the metastasis suppressor gene MKK4 in ovarian cancer.

Spillman MA, Lacy J, Murphy SK, Whitaker RS, Grace L, Teaberry V, Marks JR, Berchuck A.

Gynecol Oncol. 2007 May;105(2):312-20. Epub 2007 Feb 5.

41.

Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer.

Murphy SK, Huang Z, Wen Y, Spillman MA, Whitaker RS, Simel LR, Nichols TD, Marks JR, Berchuck A.

Mol Cancer Res. 2006 Apr;4(4):283-92.

42.

Transforming growth factor beta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk.

Spillman MA, Schildkraut JM, Halabi S, Moorman P, Calingaert B, Bentley RC, Marks JR, Murphy S, Berchuck A.

Gynecol Oncol. 2005 May;97(2):543-9.

PMID:
15863158
43.

Managing familial risk in genetic testing.

Taub S, Morin K, Spillman MA, Sade RM, Riddick FA; Council on Ethical and Judicial Affairs of the American Medical Association.

Genet Test. 2004 Fall;8(3):356-9.

PMID:
15727262
44.

Stretching the surface epithelium.

Spillman MA, Berchuck A.

J Soc Gynecol Investig. 2004 Dec;11(8):501-2. No abstract available.

PMID:
15582493
45.

Safeguards in the use of DNA databanks in genomic research.

Taub S, Morin K, Sade RM, Spillman MA; Council on Ethical and Judicial Affairs of the American Medical Association.

Genet Med. 2004 Nov-Dec;6(6):526-9. No abstract available.

PMID:
15545750
46.

Managing conflicts of interest in the conduct of clinical trials.

Morin K, Rakatansky H, Riddick FA Jr, Morse LJ, O'Bannon JM 3rd, Goldrich MS, Ray P, Weiss M, Sade RM, Spillman MA.

JAMA. 2002 Jan 2;287(1):78-84.

PMID:
11754712
47.

Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier.

Tomlinson GE, Chen TT, Stastny VA, Virmani AK, Spillman MA, Tonk V, Blum JL, Schneider NR, Wistuba II, Shay JW, Minna JD, Gazdar AF.

Cancer Res. 1998 Aug 1;58(15):3237-42.

48.

Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers.

Thai TH, Du F, Tsan JT, Jin Y, Phung A, Spillman MA, Massa HF, Muller CY, Ashfaq R, Mathis JM, Miller DS, Trask BJ, Baer R, Bowcock AM.

Hum Mol Genet. 1998 Feb;7(2):195-202.

PMID:
9425226
49.

Identification of a RING protein that can interact in vivo with the BRCA1 gene product.

Wu LC, Wang ZW, Tsan JT, Spillman MA, Phung A, Xu XL, Yang MC, Hwang LY, Bowcock AM, Baer R.

Nat Genet. 1996 Dec;14(4):430-40.

PMID:
8944023
50.

Supplemental Content

Loading ...
Support Center